Citations

Clear

3057 citation(s) found for "Cd, Johnson".

The International LAM Registry: A Component of an Innovative Web-Based Clinician, Researcher, and Patient-Driven Rare Disease Research Platform
Nurok, Michael , Eslick, Ian , Carvalho, Carlos Roberto Ribeiro de , Costabel, Ulrich , Glanville, Allan R. , Harari, Sergio , Johnson, Simon R. , Lacronique, J, Lazor, Romain , Moss, Joel , Ruoss, Stephen J. , Ryu, Jay H. , Seyama, Kuniaki , Watz, Henrik, Hohmann, Elizabeth , Moss, Frank, D'Armiento, Jeanine M , Henske, Elizabeth P. , Inoue, Yoshikazu , Xu, Kai‐Feng , Ryu, Jay H

Mayo Clinic

Lymphatic Research and Biology | March 17, 2010 | Volume: 8 | Issue: 1 | Pages: 81-87

10.1089/lrb.2009.0028 | PMID 20235890 Get It

Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome
Loeys, Bart , Gerber, Elizabeth E. , Riegert‐Johnson, Douglas L. , Iqbal, Sarah , Whiteman, Pat, McConnell, Vivienne, Chillakuri, Chandramouli , Macaya, Daniela , Coucke, Paul , Paepe, Anne De , Judge, Daniel P. , Wigley, Fredrick M. , Mardon, Helen J., Handford, Penny A. , Keene, Douglas R. , Sakai, Lynn Y. , Dietz, Harry C. , Davis, Elise C. , Judge, Daniel P

Mayo Clinic

Science Translational Medicine | March 17, 2010 | Volume: 2 | Issue: 23 | Pages: No page available

10.1126/scitranslmed.3000488 | PMID 20375004 Get It

Stiff skin syndrome, an autosomal dominant congenital form of scleroderma, is caused by mutations in the domain of fibrillin-1 that mediates integrin binding.
Islet Amyloid Polypeptide: A Review of Its Biology and Potential Roles in the Pathogenesis of Diabetes Mellitus
O’Brien, Timothy D. , Butler, Peter C. , Westermark, Per , Johnson, K. H.

Mayo Clinic

Veterinary Pathology | March 8, 2010 | Volume: 30 | Issue: 4 | Pages: 317-332

10.1177/030098589303000401 | PMID 8212454 Get It

Islet amyloidosis (IA) is the principal lesion in the endocrine pancreas of human beings with non-insulin-dependent diabetes mellitus (NIDDM) and in the similar forms of diabetes mellitus in domestic cats and macaques. As such, the delineation of the pathogenesis of this form of amyloidosis may be crucial to the understanding of the development and progression of NIDDM. Islet amyloid polypeptide (IAPP) is a recently discovered polypeptide that is the principal constituent of IA in human beings, cats, and macaques. IAPP is produced by the pancreatic β-cells and is co-packaged with insulin in the β-cell secretory vesicles. Immunohistochemical and physiologic evidence supports the notion that the β-cells are heterogenous with respect to their relative contents of insulin and IAPP. Therefore, although IAPP is co-secreted with insulin in response to a variety of well-known insulin secretogogues, the molar ratio of these two proteins that is released from the islets may vary, depending upon the glucose concentration and prevailing metabolic milieu. IAPP is highly conserved among mammalian species and has about 45% homology to another neuropeptide, calcitonin gene-related peptide. IAPP is encoded by a single-copy gene located, in the human being, on chromosome 12. IAPP is expressed as a 93 (murine)–89 (human)-amino acid prepropolypeptide that is processed enzymatically, resulting in the removal of amino- and carboxy-terminal propeptide segments. The 20–29 region of the IAPP molecule is most important in the ability of IAPP to form amyloid fibrils. The role of IAPP and IA in the pathogenesis of human NIDDM and similar forms of diabetes mellitus in cats and macaques may involve several possible mechanisms, including 1) direct physical/chemical damage to β-cells, resulting in necrosis and loss of functional islet tissue, 2) biologic activities of IAPP that oppose those of insulin or abnormally suppress insulin secretion, and 3) interference by IA deposits of passage of insulin out of β-cells and/or entrance of glucose and other secretogogues into the islet. The roles of each of these possible mechanisms have yet to be demonstrated. In addition, the physiological significance of the apparent IAPP deficiency in both insulin-dependent diabetes mellitus and NIDDM is currently unknown.
Islet Amyloid and Islet Amyloid Polypeptide in Cynomolgus Macaques ( Macaca fascicularis ): An Animal Model of Human Non-insulin-dependent Diabetes Mellitus
O’Brien, Timothy D. , Wagner, Janice D., Litwak, Kenneth N., Carlson, Cathy S. , Cefalu, William T. , Jordan, K., Johnson, Kenneth H., Butler, Peter C.

Mayo Clinic

Veterinary Pathology | March 8, 2010 | Volume: 33 | Issue: 5 | Pages: 479-485

10.1177/030098589603300501 | PMID 8885173 Get It

To further characterize spontaneous diabetes mellitus in cynomolgus macaques ( Macaca fascicularis) as a model for human non-insulin-dependent diabetes mellitus (NIDDM), we evaluated the morphologic characteristics of the endocrine pancreas of 4 diabetic and 12 age-matched nondiabetic cynomolgus macaques. In addition, the cDNA-predicted amino acid sequence for islet amyloid polypeptide (IAPP) of this species was determined. Islet amyloid deposits exhibiting typical congophilia and green birefringence were found in 4/4 diabetic animals and in 8/12 nondiabetics. Islet amyloid deposits were significantly more extensive in the diabetic macaques ( P = 0.001), in which they occupied a mean of 60% of the islet area. In contrast, in the nondiabetic group the maximum islet area occupied by amyloid was 24% (group mean = 6.8%), with four animals having no detectable islet amyloid. Amyloid deposits consistently showed immunoreactivity for IAPP but not for insulin. Comparisons between group means for diabetic versus nondiabetic macaques showed significantly greater islet area ( P = 0.01, 85,390 versus 36,540 μm 2 ) and significantly greater islet area fraction ( P = 0.02, 0.065 versus 0.032) for the diabetic group. The cDNA-predicted amino acid sequence for cynomolgus IAPP was identical to that previously reported for pig-tail macaques ( M. nemestrina) and had 92%, 86%, and 84% amino acid sequence identity with human, domestic cat, and murine IAPPs, respectively. These findings support the use of cynomolgus macaques as an animal model of human NIDDM.
Prostaglandin E2 administered by subcutaneous pellets causes local inflammation and systemic bone loss: A model for inflammation-induced bone disease
Desimone, Daniel P., Greene, Virginia S., Hannon, Kathleen S., Turner, Russell T. , Bell, Norman H.

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 8 | Issue: 5 | Pages: 625-634

10.1002/jbmr.5650080514 | PMID 8511990 Get It

AbstractThe effects of prostaglandin E2 (PGE2) given in controlled-release pellets or by daily sc injection for 21 days on mineral homeostasis and bone histomorphometry were compared in 7-week-old female rats. Sham operation and ovariectomy were performed at the beginning of the studies. In experiment 1, 7.5 mg PGE2 or drug-free, controlled-release pellets were implanted sc at the back of the neck on day 7. In experiment 2, 3 mg/kg body weight of PGE2 or vehicle was injected sc daily beginning on day 7. The animals were sacrificed on day 28 of the two experiments, and the tibiae were removed for histomorphometric analysis of the diaphysis and metaphysis. When administered by pellets in experiment 1, PGE2 lowered serum 1,25-dihydroxyvitamin D and did not influence weight gain, serum calcium, phosphorus, or magnesium, cross-sectional or medullary areas, periosteal bone formation and apposition rates, endosteal bone formation and apposition rates, or endosteal tetracycline-labeled perimeter. PGE2 lowered cancellous bone area and cancellous bone perimeter in both the sham-operated and ovariectomized rats. In contrast, when administered by sc injection in experiment 2, PGE2 reduced weight gain, increased serum magnesium, increased cortical area, and reduced medullary area without changing cross-sectional area, increased periosteal bone formation and apposition rates and endosteal bone and apposition rates, did not alter endosteal tetracycline-labeled perimeter, and increased cancellous bone area and cancellous bone perimeter in both sham-operated and ovariectomized animals. PGE2 produced local inflammation when given by pellets, and the serum concentration of 13,14-dihydro-15-ketoprostaglandin E2, the major metabolite of PGE2, increased when PGE2 was given by sc injection but not when administered by pellets. Thus, PGE2 given sc by controlled-release pellets (1) produces local inflammation and systemic bone loss without increasing PGE2 systemically and (2) provides a model for inflammation-induced loss of cancellous bone. The results also indicate that the pellet is not a valid means for the delivery of PGE2 to the general circulation.
Ontogeny of the 1,25-dihydroxyvitamin D3 receptor in fetal rat bone
Grande, Joseph P. , Roche, Patrick C. , Kumar, Rajiv , Johnson, Julie A. , Kumar, Rajiv

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 11 | Issue: 1 | Pages: 56-61

10.1002/jbmr.5650110109 | PMID 8770697 Get It

Abstract To gain insights into 1,25-dihydroxyvitamin D3 receptor (VDR) function during fetal bone development, we examined fetal rat tissues from gestational days 13–21 for the presence and distribution of VDR using immuno-histochemistry. Prior to ossification, VDR epitopes were observed in the mesenchyme condensing to form skeletal tissues, on day 13 in the developing vertebral column and limbs, and on day 17 of gestation in developing calvaria. Immunostaining for VDR was seen in proliferating and hypertrophic chondrocytes and in osteoblasts of limb buds and the vertebral column by day 17 of gestation. In calvaria, VDR epitopes were observed in osteoblasts by gestational day 19. VDR immunostaining was also evident in the skin of fetal limbs at all gestational ages examined. We show for the first time that the VDR appears very early in the developing fetal rat skeleton, suggesting that the VDR, in concert with its ligand, 1,25-dihydroxyvitamin D3, may play a role in the differentiation of mesenchymal precursors into bone tissue.
Process Improvement: What Is It, Why Is It Important, and How Is It Done?
Aakre, Kenneth T., Roberts, Catherine C. , Patel, Maitray D. , Krecke, Karl N. , Johnson, Charles D. , Miranda, Rafael , Patel, Maitray D

Mayo Clinic

American Journal of Roentgenology | January 21, 2010 | Volume: 194 | Issue: 2 | Pages: 461-468

10.2214/ajr.09.3213 | PMID 20093610 Get It

Influence of Locomotor Muscle Metaboreceptor Stimulation on the Ventilatory Response to Exercise in Heart Failure
Olson, Thomas P. , Joyner, Michael J. , Johnson, Bruce D. , Joyner, Michael J

Mayo Clinic

Circulation: Heart Failure | January 9, 2010 | Volume: 3 | Issue: 2 | Pages: 212-219

10.1161/circheartfailure.109.879684 | PMID 20061520 Get It

Background— Whether locomotor muscle afferent neural activity contributes to exercise hyperpnea and symptoms of dyspnea in heart failure (HF) is controversial. We examined the influence of metaboreceptor stimulation on ventilation with and without maintaining end-exercise end-tidal CO 2 levels. Methods and Results— Eleven patients with HF aged 51±5 years (ejection fraction, 32±3%; New York Heart Association class, 1.6±0.2) and 11 age- and gender-matched healthy control participants aged 43±3 years were studied. Participants underwent 3 steady-state cycling sessions at 60% of peak oxygen consumption for 4 minutes. The first exercise session was a baseline control trial. Bilateral thigh tourniquets were inflated to suprasystolic pressure at end exercise for 2 minutes during 2 of the trials (regional circulatory occlusion) with the addition of inspired CO 2 to maintain end-exercise partial pressure of end-tidal CO 2 during 1 trial (regional circulatory occlusion+CO 2 ). Minute ventilation was measured continuously throughout each trial. At 2 minutes postexercise during the baseline control trial in patients with HF, minute ventilation was 54% of end exercise, whereas the control group averaged 41% ( P =0.11). During regional circulatory occlusion in patients with HF, minute ventilation was 60% of end exercise; however, the control group averaged 35% ( P <0.001). During regional circulatory occlusion+CO 2 , the minute ventilation of patients with HF averaged 67% of end exercise, whereas the control group averaged 44% ( P <0.001). Conclusion— These data suggest that increased afferent neural activity from the large locomotor muscles associated with metabolites generated during exercise contribute to the augmented ventilatory response to exercise in patients with HF.
Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications
Wen, Sheron, Beitelshees, Amber L. , Zineh, Issam, Gums, John G. , Hall, Karen , Parekh, Vishal, Chapman, Arlene B. , Boerwinkle, Eric , Johnson, Julie A. , Beitelshees, Amber L. , Cooper‐DeHoff, Rhonda M. , Turner, Stephen T. , Gong, Yan , Chapman, Arlene B.

Mayo Clinic

Hypertension | November 17, 2009 | Volume: 55 | Issue: 1 | Pages: 61-68

10.1161/hypertensionaha.109.139592 | PMID 19917874 Get It

We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of atenolol monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and uric acid levels were measured at baseline and after monotherapy and combination therapy. Outcomes included new occurrence of and predictors for new cases of glucose ≥100 mg/dL (impaired fasting glucose), triglyceride ≥150 mg/dL, high-density lipoprotein ≤40 mg/dL for men or ≤50 mg/dL for women, or new-onset diabetes mellitus according to the presence or absence of abdominal obesity. Abdominal obesity was present in 167 (58%) of 395 patients. Regardless of strategy, in those with abdominal obesity, 20% had impaired fasting glucose at baseline compared with 40% at the end of study ( P <0.0001). Proportion with triglycerides ≥150 mg/dL increased from 33% at baseline to 46% at the end of study ( P <0.01). New-onset diabetes mellitus occurred in 13 patients (6%) with and in 4 patients (2%) without abdominal obesity. Baseline levels of glucose, triglyceride, and high-density lipoprotein predicted adverse outcomes, and predictors for new-onset diabetes mellitus after monotherapy in those with abdominal obesity included hydrochlorothiazide strategy (odds ratio: 46.91 [95% CI: 2.55 to 862.40]), female sex (odds ratio: 31.37 [95% CI: 2.10 to 468.99]), and uric acid (odds ratio: 3.19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity.
Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure
Packer, Douglas L. , Prutkin, Jordan M. , Hellkamp, Anne S., Mitchell, L. Brent, Bernstein, Robert, Wood, Freda, Boehmer, John , Carlson, Mark D., Frantz, Robert P. , McNulty, Steve E., Rogers, Joseph G. , Anderson, Jill, Johnson, George, Walsh, Mary Norine , Poole, Jeanne E. , Mark, Daniel B. , Lee, Kerry L. , Bardy, Gust H., Frantz, Robert P , Mark, Daniel B

Mayo Clinic

Circulation | November 16, 2009 | Volume: 120 | Issue: 22 | Pages: 2170-2176

10.1161/circulationaha.109.853689 | PMID 19917887 Get It

Background— The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces all-cause mortality in patients with New York Heart Association class II/III heart failure and a left ventricular ejection fraction ≤35% on optimal medical therapy. Whether ICD therapy reduced sudden death caused by ventricular tachyarrhythmias without affecting heart failure deaths in this population is unknown. Methods and Results— SCD-HeFT randomized 2521 subjects to placebo, amiodarone, or shock-only, single-lead ICD therapy. Over a median follow-up of 45.5 months, a total of 666 deaths occurred, which were reviewed by an Events Committee and initially categorized as cardiac or noncardiac. Cardiac deaths were further adjudicated as resulting from sudden death presumed to be ventricular tachyarrhythmic, bradyarrhythmia, heart failure, or other cardiac causes. ICD therapy significantly reduced cardiac mortality compared with placebo (adjusted hazard ratio, 0.76; 95% confidence interval, 0.60 to 0.95) and tachyarrhythmia mortality (adjusted hazard ratio, 0.40; 95% confidence interval, 0.27 to 0.59) and had no impact on mortality resulting from heart failure or noncardiac causes. The cardiac and tachyarrhythmia mortality reductions were evident in subjects with New York Heart Association class II but not in subjects with class III heart failure. The reduction in tachyarrhythmia mortality with ICD therapy was similar in subjects with ischemic and nonischemic disease. Compared with placebo, amiodarone had no significant effect on any mode of death. Conclusions— ICD therapy reduced cardiac mortality and sudden death presumed to be ventricular tachyarrhythmic in SCD-HeFT and had no effect on heart failure mortality. Amiodarone had no effect on all-cause mortality or its cause-specific components, except an increase in non-cardiac mortality in class III patients. Clinical Trial Registration Information— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000609.